Refine
Year of publication
Document Type
- Article (59)
- Conference Proceeding (4)
Language
- English (63)
Has Fulltext
- yes (63)
Is part of the Bibliography
- no (63)
Keywords
- glioblastoma (5)
- Epilepsy (3)
- epilepsy (3)
- glioma (3)
- meningioma (3)
- quantitative MRI (3)
- Fasting (2)
- Glioblastoma (2)
- Glioma (2)
- Glucose (2)
- IDH mutation (2)
- Ketogenic diet (2)
- Leptin (2)
- MRI (2)
- Radiation (2)
- cerebellum (2)
- hypoxia (2)
- magnetic resonance imaging (2)
- medulloblastoma (2)
- multiple sclerosis (2)
- neurodegeneration (2)
- targeted therapy (2)
- 19F MR spectroscopy (1)
- 1H MR spectroscopy (1)
- 2-hydroxyglutarate (1)
- 4-1BB (1)
- APT-CEST (1)
- ASPECTS (1)
- ATP (1)
- Abusive head trauma (AHT) (1)
- Acute (1)
- Aerobic exercise training (1)
- Analogue modelling (1)
- Anticonvulsants (1)
- Ataxia (1)
- Benign enlargement of the subarachnoid spaces (BESS) (1)
- Brain metastasis (1)
- Brain tumor (1)
- CD137 (1)
- CEST EPI (1)
- CLOCC (1)
- CMS (1)
- COVID-19 (1)
- Cellular energy metabolism (1)
- Cerebellum (1)
- Cerebral hypoperfusion (1)
- Cochlear implant (1)
- Coeval folding and boudinage (1)
- Cognition (1)
- Cognitive impairment (1)
- Comparative analysis (1)
- Complications (1)
- Constriction (1)
- Cortical degeneration (1)
- Cortical thickness (1)
- DNA methylation (1)
- DTI (1)
- DWI (1)
- Deep neural network (1)
- Deformation oblique layer (1)
- Dementia (1)
- Differential diagnosis (1)
- Dome-and-basin structure (1)
- Dravet (1)
- Dysphagia (1)
- Encephalopathy (1)
- Epilepsy center (1)
- Gradient boosting (1)
- HOD (1)
- Head bandage (1)
- Health care (1)
- Hemosiderin (1)
- Holmes tremor (1)
- IDH1 inhibitor (1)
- Immune checkpoint inhibitors (1)
- Immunotherapy (1)
- Isocitrate dehydrogenase (1)
- KPS (1)
- MR spectroscopy (1)
- MR-spectroscopy (1)
- MRI patterns of gliomas (1)
- MTRasym (1)
- Magnet dislocation (1)
- Magnetic resonance imaging (1)
- Magnetic resonance spectroscopic imaging (1)
- Malignant meningioma (1)
- Medical research (1)
- Melanoma (1)
- Meningioma (1)
- Metabolic diseases (1)
- Microstructural impairment (1)
- Molecular matched therapy (1)
- Molecular profiling (1)
- Multi-syndrome classification (1)
- Neonatal brain damage (1)
- Neural circuits (1)
- Neurodegenerative syndromes (1)
- Neurology (1)
- Neuropilin (1)
- Neuroscience (1)
- Non-abusive head trauma (NAHT) (1)
- Non-cylindrical folds (1)
- Non-expert MRI (1)
- Older adults (1)
- Oxygen extraction fraction (1)
- PWI (1)
- Pneumonia (1)
- Prevention (1)
- Proton density (1)
- Pseudoprogression (1)
- Psychology (1)
- Psychometric tests (1)
- Quantitative (q)T2 mapping (1)
- Quantitative MRI (1)
- Quantitative magnetic resonance imaging (1)
- RESLES (1)
- Radiosurgery (1)
- Random forest (1)
- Referral (1)
- Relaxometry (1)
- Reproducibility (1)
- SKALE score (1)
- STAMPE2 (1)
- Scanner models (1)
- Seizure (1)
- Siderosis (1)
- Small vessel disease (1)
- Stroke (1)
- Support vector machine (1)
- Swallowing (1)
- T2 (1)
- TBSS (1)
- Targeted therapy (1)
- VEGF (1)
- VEGF receptors (1)
- [18F]FET PET (1)
- adult (1)
- amide proton transfer (1)
- amino acid PET (1)
- anaemia (1)
- anticonvulsants (1)
- artificial intelligence (1)
- aspiration (1)
- brain imaging (1)
- brain metastases (1)
- brain metastasis (1)
- brain tumor (1)
- brainstem (1)
- central nervous system (1)
- cerebellar mutism (1)
- cerebral pseudoprogression (1)
- cerebral vasospasm (CVS) (1)
- cerebrospinal fluid (1)
- chemotherapy (1)
- child (1)
- clinical outcome (1)
- clinical trial (1)
- computed tomography (1)
- connectivity (1)
- corpus callosum (1)
- cortex (1)
- cortex, gray matter (1)
- cortical malformation (1)
- cortical thickness (1)
- delayed cerebral ischemia (DCI) (1)
- diet (1)
- diffusion tensor imaging (1)
- double inversion recovery (DIR) (1)
- dysphagia (1)
- echo planar imaging (1)
- edema (1)
- elderly (1)
- encephalopathy (1)
- fasting (1)
- focal cortical dysplasia (1)
- focal cortical dysplasia (FCD) (1)
- fractional anisotropy (1)
- gadolinium‐based contrast agent (1)
- gray‐white matter blurring (1)
- grisel syndrome (1)
- healthcare system (1)
- hemispherotomy (1)
- image-guided tissue acquisition (1)
- imaging protocol (1)
- immune checkpoint inhibitors (ICI) (1)
- immune related adverse events (irAE) (1)
- immunotherapy (1)
- infiltration (1)
- invasive mold infection (1)
- juvenile brain lesion (1)
- ketogenic (1)
- ketone body (1)
- longitudinal relaxation time T1 (1)
- magnetic resonance imaging of the brain (1)
- malignant glioma (1)
- mean diffusivity (1)
- melanoma (1)
- metabolism (1)
- mitochondria (1)
- multislice imaging (1)
- murine model (1)
- neuroimaging (1)
- neurological complication (1)
- neurological side effects (1)
- neurosurgery (1)
- neurysmal subarachnoid hemorrhage (aSAH) (1)
- nontraumatic atlantoaxial rotatory subluxation (1)
- oedema (1)
- outcome (1)
- pH (1)
- palatal tremor (1)
- pandemic (1)
- patterns of progression (1)
- perioperative ischemia (1)
- plasticity (1)
- posterior fossa tumor (1)
- quantitative T1 mapping (1)
- quantitative T1‐difference maps (1)
- quantitative magnetic resonance imaging (1)
- radiotherapy (1)
- randomized (1)
- red blood cells (1)
- regorafenib (1)
- regorafenib csf concentration (1)
- relaxometry (1)
- seizures (1)
- small molecule inhibitor (1)
- subgrouping (1)
- swallowing (1)
- torticollis (1)
- tractography (1)
- transfusion (1)
- treatment-related changes (1)
- tumor necrosis factor receptor superfamily member 9 (1)
- tumor progression (1)
Institute
- Medizin (62)
- MPI für Hirnforschung (2)
- Sportwissenschaften (2)
- Georg-Speyer-Haus (1)
- Geowissenschaften (1)
Purpose: The prospective, randomized ERGO2 trial investigated the effect of calorie-restricted ketogenic diet and intermittent fasting (KD-IF) on re-irradiation for recurrent brain tumors. The study did not meet its primary endpoint of improved progression-free survival in comparison to standard diet (SD). We here report the results of the quality of life/neurocognition and a detailed analysis of the diet diaries. Methods: 50 patients were randomized 1:1 to re-irradiation combined with either SD or KD-IF. The KD-IF schedule included 3 days of ketogenic diet (KD: 21–23 kcal/kg/d, carbohydrate intake limited to 50 g/d), followed by 3 days of fasting and again 3 days of KD. Follow-up included examination of cognition, quality of life and serum samples. Results: The 20 patients who completed KD-IF met the prespecified goals for calorie and carbohydrate restriction. Substantial decreases in leptin and insulin and an increase in uric acid were observed. The SD group, of note, had a lower calorie intake than expected (21 kcal/kg/d instead of 30 kcal/kg/d). Neither quality of life nor cognition were affected by the diet. Low glucose emerged as a significant prognostic parameter in a best responder analysis. Conclusion: The strict caloric goals of the ERGO2 trial were tolerated well by patients with recurrent brain cancer. The short diet schedule led to significant metabolic changes with low glucose emerging as a candidate marker of better prognosis. The unexpected lower calorie intake of the control group complicates the interpretation of the results. Clinicaltrials.gov number: NCT01754350; Registration: 21.12.2012.
Purpose: The prospective, randomized ERGO2 trial investigated the effect of calorie-restricted ketogenic diet and intermittent fasting (KD-IF) on re-irradiation for recurrent brain tumors. The study did not meet its primary endpoint of improved progression-free survival in comparison to standard diet (SD). We here report the results of the quality of life/neurocognition and a detailed analysis of the diet diaries. Methods: 50 patients were randomized 1:1 to re-irradiation combined with either SD or KD-IF. The KD-IF schedule included 3 days of ketogenic diet (KD: 21–23 kcal/kg/d, carbohydrate intake limited to 50 g/d), followed by 3 days of fasting and again 3 days of KD. Follow-up included examination of cognition, quality of life and serum samples. Results: The 20 patients who completed KD-IF met the prespecified goals for calorie and carbohydrate restriction. Substantial decreases in leptin and insulin and an increase in uric acid were observed. The SD group, of note, had a lower calorie intake than expected (21 kcal/kg/d instead of 30 kcal/kg/d). Neither quality of life nor cognition were affected by the diet. Low glucose emerged as a significant prognostic parameter in a best responder analysis. Conclusion: The strict caloric goals of the ERGO2 trial were tolerated well by patients with recurrent brain cancer. The short diet schedule led to significant metabolic changes with low glucose emerging as a candidate marker of better prognosis. The unexpected lower calorie intake of the control group complicates the interpretation of the results. Clinicaltrials.gov number: NCT01754350; Registration: 21.12.2012.
Background: The inclusion of immune checkpoint inhibitors (ICIs) in therapeutic algorithms has led to significant survival benefits in patients with various metastatic cancers. Concurrently, an increasing number of neurological immune related adverse events (IRAE) has been observed. In this retrospective analysis, we examine the ICI-induced incidence of cerebral pseudoprogression and propose a classification system.
Methods: We screened our hospital information system to identify patients with any in-house ICI treatment for any tumor disease during the years 2007-2019. All patients with cerebral MR imaging (cMRI) of sufficient diagnostic quality were included. cMRIs were retrospectively analyzed according to immunotherapy response assessment for neuro-oncology (iRANO) criteria.
Results: We identified 12 cases of cerebral pseudoprogression in 123 patients treated with ICIs and sufficient MRI. These patients were receiving ICI therapy for lung cancer (n=5), malignant melanoma (n=4), glioblastoma (n=1), hepatocellular carcinoma (n=1) or lymphoma (n=1) when cerebral pseudoprogression was detected. Median time from the start of ICI treatment to pseudoprogression was 5 months. All but one patient developed neurological symptoms. Three different patterns of cerebral pseudoprogression could be distinguished: new or increasing contrast-enhancing lesions, new or increasing T2 predominant lesions and cerebral vasculitis type pattern.
Conclusion: Cerebral pseudoprogression followed three distinct patterns and was detectable in 3.2% of all patients during ICI treatment and in 9.75% of the patients with sufficient brain imaging follow up. The fact that all but one of the affected patients developed neurological symptoms, which would be classified as progressive disease according to iRANO criteria, mandates vigilance in the diagnosis and treatment of ICI-induced cerebral lesions.